ARNA Arena Pharmaceuticals Inc.

73.69
+0.65  (+1%)
Previous Close 73.04
Open 73.2
52 Week Low 32.95
52 Week High 74.635
Market Cap $4,248,002,788
Shares 57,646,937
Float 57,598,149
Enterprise Value $3,124,966,787
Volume 685,928
Av. Daily Volume 543,155
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Etrasimod
Atopic dermatitis (AD)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
APD418
Acute heart failure (AHF)
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Olorinab
Irritable Bowel Syndrome
Phase 2b
Phase 2b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Etrasimod (ELEVATE UC 12)
Ulcerative colitis
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Etrasimod (ELEVATE UC 52)
Ulcerative colitis
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Etrasimod
Alopecia areata (AA)
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Etrasimod
Crohn's disease
Phase 2b
Phase 2b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Etrasimod
Eosinophilic esophagitis (EoE)
Phase 2b
Phase 2b
Phase 2b trial to be initiated in 2H 2020 dependent on COVID situation.
Lorcaserin
Obesity
Approved
Approved
Approved June 27, 2012.

Latest News

  1. SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that on September 15, 2020, the Compensation Committee of its Board of Directors granted to nine new employees inducement stock options to purchase an aggregate of 68,825 shares of its common stock and 12,420 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of September 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).

    The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of $69.25 per share, the closing…

    SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that on September 15, 2020, the Compensation Committee of its Board of Directors granted to nine new employees inducement stock options to purchase an aggregate of 68,825 shares of its common stock and 12,420 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of September 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).

    The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of $69.25 per share, the closing price of Arena's common stock on the grant date, and vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in substantially equal monthly installments over the following 36 months, subject to the new employee's continued service with Arena through the applicable vesting dates. The inducement RSUs vest over four years, with 25% of the shares vesting on the first quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarterly installments occurring on the following 12 quarterly vesting dates, subject to the new employee's continued service with Arena through the applicable vesting dates. The inducement stock options and inducement RSUs are subject to the terms and conditions of Arena's Amended and Restated 2020 Long-Term Incentive Plan.

    About Arena Pharmaceuticals

    ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.

    In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.

    ARENA - Care More. Act Differently.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Corporate Contact:

    Megan E. Knight

    Arena Pharmaceuticals, Inc.

    Director, Investor Relations 



    858.210.3635

    Arena Media Contact: 

     

    858.453.7200 

    Arena Pharmaceuticals Logo

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301134126.html

    SOURCE Arena Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  2. SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Wednesday, September 23, at 1:45 PM ET.                                         

    A live audio webcast of the presentation will be posted under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event.

    About Arena Pharmaceuticals

    ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.

    In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.

    ARENA - Care More. Act Differently.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's participation in upcoming investor conference and Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Corporate Contact:

    Megan E. Knight

    Arena Pharmaceuticals, Inc.

    Director, Investor Relations 



    858.210.3635

    Arena Media Contact: 

     

    858.453.7200 

    Arena Pharmaceuticals Logo

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-jefferies-virtual-next-generation-ibd-therapeutics-summit-301133917.html

    SOURCE Arena Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  3. SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderately to severely active ulcerative colitis. ELEVATE UC 12 is the second of two pivotal trials within the Phase 3 ELEVATE UC registrational program to assess the safety and efficacy of etrasimod 2 mg.

    "The enrollment of the first patient in ELEVATE UC 12 is an important milestone in the development of etrasimod, an oral, once-daily option, with a novel mechanism of action," stated Timothy Ritter

    SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderately to severely active ulcerative colitis. ELEVATE UC 12 is the second of two pivotal trials within the Phase 3 ELEVATE UC registrational program to assess the safety and efficacy of etrasimod 2 mg.

    "The enrollment of the first patient in ELEVATE UC 12 is an important milestone in the development of etrasimod, an oral, once-daily option, with a novel mechanism of action," stated Timothy Ritter, MD, Senior Medical Director, Department of Clinical Research and Education, GI Alliance Research. "There is a significant unmet need for patients with moderate to severe ulcerative colitis, and I look forward to seeing the results of Arena's Phase 3 program."

    "We are pleased to initiate the ELEVATE UC 12 Phase 3 trial, the second of two pivotal trials that will bring us one step closer to our goal of delivering an oral, once-daily, durable therapeutic option for patients living with ulcerative colitis," stated Chris Cabell, MD, MHS, FACC, Executive Vice President, Head of Research and Development, and Chief Medical Officer at Arena. "This is a significant milestone for Arena as the progress confirms that the ELEVATE UC registrational program, including ELEVATE UC 12 and UC 52 trials, remains on track for data by year-end 2021."

    About ELEVATE UC 12

    ELEVATE UC 12 is one of two pivotal trials that are part of the ELEVATE UC global Phase 3 registrational program. ELEVATE UC 12 is a 2:1 randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of etrasimod 2 mg once-daily in subjects with moderately to severely active ulcerative colitis (UC) defined as a baseline 3-domain, modified Mayo Score of 4 to 9 with an endoscopic score of 2 or more, and a rectal bleeding score of 1 or more. The primary objective of this trial is to assess the safety and efficacy of etrasimod on clinical remission at 12 weeks assessed by the FDA-required, 3-domain, modified Mayo Score, which is similar to the primary endpoint in the Phase 2 OASIS trial. Key secondary measures include the efficacy of etrasimod on clinical response, symptomatic response and remission, endoscopic changes, corticosteroid-free remission, and a total healing in these subjects. The ELEVATE UC program is being conducted in approximately 450 sites across more than 40 countries.

    About Etrasimod

    Etrasimod (APD334) is a next generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena, and designed for optimized pharmacology and engagement of S1P receptor 1, 4 and 5 which may lead to an improved efficacy and safety profile.

    Etrasimod provides systemic and local effects on specific immune cell types and has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn's disease, atopic dermatitis, and alopecia areata.   

    Etrasimod is an investigational compound that is not approved for any use in any country.

    About Arena Pharmaceuticals

    ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.

    In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.

    ARENA - Care More. Act Differently.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements may be identified by words such as "evaluating," "potential," "look forward to," "will," "goal," "on track to," and "may," and include, without limitation, statements about the following: the opportunity, development and potential of etrasimod, including regarding its design, its therapeutic potential in immune-mediated inflammatory diseases such as ulcerative colitis (UC), Crohn's disease, atopic dermatitis, and alopecia areata, its ability to  satisfy an unmet medical or clinical need, and its safety and efficacy; the ELEVATE UC program and ELEVATE UC 52 and ELEVATE UC 12 trials, including enrollment, study sites and trial design; the significance of the trials and their initiation; and Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: clinical trials and other studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Arena's drug candidates may not advance in development or be approved for marketing; enrolling patients in Arena's ongoing and intended clinical trials is competitive and challenging; the duration and severity of the coronavirus disease (COVID-19) pandemic, including but not limited to its impact on Arena's clinical trials and operations, the operations of Arena's suppliers, partners, collaborators, licensees, and the capital markets, which in each case remains uncertain; risks related to developing and commercializing drugs; Arena may need additional funds to advance all of its programs; risks and uncertainties relating to cash and revenues that may be generated from product sales or other sources, including the impact of competition; risks related to unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; topline data may not accurately reflect the complete results of a particular study or trial; satisfactory resolution of litigation or other disagreements with others; government and third-party payor actions, including relating to reimbursement and pricing; risks related to relying on licenses or collaborative arrangements, including lack of control and potential disputes; the entry into or modification or termination of licenses or collaborative arrangements; and Arena's and third parties' intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to Arena's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, which was filed with the SEC on August 5, 2020. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Corporate Contact:

    Megan E. Knight

    Arena Pharmaceuticals, Inc.

    Director, Investor Relations 

     

    858.210.3635

    Arena Media Contact: 

     

    858.453.7200 

    Arena Pharmaceuticals Logo

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-first-subject-dosed-in-elevate-uc-12-global-phase-3-trial-evaluating-etrasimod-in-ulcerative-colitis-301131854.html

    SOURCE Arena Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  4. CannabisNewsWire Editorial Coverage: A recent Data Bridge Market Research report notes that the once-hot cannabis industry looks to be heating up again — in a big way. The report includes predictions that the global legal marijuana market will total more than $90 billion by 2027. Smart companies are jostling for a strong position in this explosive space, […]

    CannabisNewsWire Editorial Coverage: A recent Data Bridge Market Research report notes that the once-hot cannabis industry looks to be heating up again — in a big way. The report includes predictions that the global legal marijuana market will total more than $90 billion by 2027. Smart companies are jostling for a strong position in this explosive space, looking to leverage their expertise…

    CannabisNewsWire Editorial Coverage: A recent Data Bridge Market Research report notes that the once-hot cannabis industry looks to be heating up again — in a big way. The report includes predictions that the global legal marijuana market will total more than $90 billion by 2027. Smart companies are jostling for a strong position in this explosive space, […]

    CannabisNewsWire Editorial Coverage: A recent Data Bridge Market Research report notes that the once-hot cannabis industry looks to be heating up again — in a big way. The report includes predictions that the global legal marijuana market will total more than $90 billion by 2027. Smart companies are jostling for a strong position in this explosive space, looking to leverage their expertise to capitalize on opportunities the multi-billion-dollar sector provides. Recognizing key challenges in the industry, including availability of often subpar quality of available product along with the high cost of development and land acquisition, Pac Roots Cannabis Corp. (CSE:PACR) (PACR Profile) is focusing on its state-of-the-art genetics to ensure  production of premium-quality products. In addition, the company is relying on science and key strategic partnerships to eliminate quality and cost barriers to success. Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBFhas received regulatory approval for its acquisition of one of 10 vertically integrated licenses in New York while Tilray Inc. (NASDAQ:TLRY) has received complete GMP certification at its EU campus. Aurora Cannabis Inc.  (NYSE:ACB) (TSX:ACB) has almost completed the first phase of a business transformation focused on setting up the company for success in this burgeoning space. And in the medical-use sector, Arena Pharmaceuticals Inc. (NASDAQ:ARNA) is pursuing a significant unmet opportunity for a targeted IBS pain treatment using olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2).

    • Absolute access to one of Canada's largest live, genetic cannabis library provides PACR with more than 350 lab-tested, field-tested cultivars.
    • Superior flowers are key to producing superior cannabis products.
    • Pac Roots chooses best outdoor growing climates in Canada for its growing cultivation operations.

    Click here to view the custom infographic of the Pac Roots Cannabis Corp. (CSE:PACR) editorial.

    Delivering the Best

    While it may seem obvious, the availability of high-quality flowers is essential to the process of producing high-quality cannabis products. Yet as demand for cannabis products has increased and more companies have entered the flourishing space, the quality of raw cannabis product may actually be slipping as companies focus more on market share than quality.

    Pac Roots Cannabis Corp. (CSE:PACR) is committed to delivering the finest cannabis genetics to its customers, preserving the superiority of its carefully cultivated elite strains while also working to introduce unmatched new strains. While some companies may work to be the largest cannabis grower, Pac Roots believes that product quality is paramount. With demand for premium products at an all-time high, Pac Roots is dedicated to becoming a leader in the premium-cannabis space.

    The company achieves this objective in part through its strategic licensing agreement with Phenome One Corp, which gives Pac Roots complete access to one of Canada's largest live, genetic cannabis library with both field- and lab-tested, selectively bred cultivars. Pac Roots utilizes the cultivars in the Phenome One library to grow, breed and clone its own distinctive brands. Through vigilant breeding and cultivation, Pac Roots offers everything from CBD-dominant plants with rare terpene profiles and soaring 30%-plus THC giants to West Coast outdoor, botrytis-resistant plants.

    Pac Roots and Phenome One are developing exclusive strains with several beneficial characteristics. The impressive catalog consists of more than 350 tested cultivars; approximately 50 are in the super-elite category. The aim for the partnership is to offer the highest-quality cultivars that have been proven and tested under variable commercial conditions to provide the greatest resilience. The two companies share a dedication to delivering rich THC and CBD cultivars with unique terpene profiles while continuing to attain industry-leading GPW yield.

    Key to Quality Cannabis

    Superior genetics isn't the only key to cultivating quality cannabis. Optimized farming systems are crucial in the pursuit of quality product. Pac Roots works closely with carefully selected partners to improve cultivation through proprietary methods, including the following fundamental components:

    • Nutrients are custom formulated from raw salts for specific cultivars.
    • Systematic planting of young, hardy cultivars, measuring up to 18 inches, which provides maximum opportunity for growth and resilience.
    • Row compaction and mowing for weed control, enabling a selected harvest
    • Complex irrigation systems with direct-nutrient and spring-water delivery to each plant site.

    In addition to observing tested and refined cultivation methods, Pac Roots carefully selected its cultivation sites, focuses its operations on the finest outdoor growing climates in Canada, including the South Okanagan Valley and the Fraser Valley Regional District.

    Golden Mile Cultivation

    Known as the Golden Mile and now referred to as the Napa Valley of the North, the South Okanagan Valley in British Columbia is the location of Rock Creek Farms, a 100-acre, premium-hemp, joint venture that Pac Roots started in May 2020 after receiving its hemp cultivation license from Health Canada.

    Planting began in June when approximately 130,000 premium-hemp CBD seedlings, which had been sown earlier in greenhouses to ensure optimum growth and reduce environmental impact, were systematically planted across two 50-acre parcels. With harvesting projected to begin in October, the hemp plantation crop is expected to be between 500,000 and 700,00 pounds of biomass; 100% of that yield is already under contract with a processor at fair market value.

    "It has been a busy for months since listing on the CSE in early May 2020," said Pac Roots CEO Patrick Elliott. "We are proud to have a healthy crop and remain bullish on delivering a premium, high-yielding product to our customer. In early 2020, we had a goal of becoming a revenue generator in 2020 as market appetite was evolving towards a cash flow scenario and realizing on projected forecasts as paramount to survival in this industry. We are privileged to be involved with our strategic partners at Rock Creeks Farms, Phenome One and Speakeasy Cannabis Club as a production scenario in our first year of operation would not have been possible without the generous leasing of land, equipment, licenses, infrastructure, genetics, operations team, management and expertise to round off the joint venture."

    Fraser Valley Production

    In addition, the company is slated to soon complete a share purchase agreement of 250 acres of prestigious land in the Fraser Valley Regional District (FVRD) of British Columbia. The agreement, made with 1088070 BC. Ltd. outlines Pac Roots' plans to acquire all of the issued and outstanding shares of 1088, which owned nine parcels of pristine property in FVRD, one of the most productive and intensively farmed areas in Canada. The area offers the finest soil, a favorable climate, ample water and a local market of an estimated 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

    "The addition of such a substantial package of land to our portfolio is a major step for Pac Roots," said Elliott. "We are pleased to have the opportunity to add significant acreage with an acquisitional cost base of $9,600 per acre. This land has no zoning restrictions and is not situated within the Agricultural land reserve, which provides for infinite development possibilities."

    The acquisition of the 250 FVRD acres combined with the 100-acre hemp joint venture in Rock Creek, along with the company's plans for an indoor cultivation facility in Lake Country, British Columbia, demonstrates a long pipeline of development projects for Pac Roots. Through these recent achievements, the growing company is confirming its ability to optimize cultivation with seasoned expertise. Its commitment to maximizing yield while lowering production costs seems evident throughout Pac Roots' strategic growth plan.

    With demand for superior cannabis products only expected to increase as large-scale growers appear incapable of delivering a premium-grade flower, Pac Roots looks to have firmly established its focus on offering the best crops available and developing the future of genetics. "Preserving the excellence of our elite strains while introducing the highest quality of new strains to the public is our passion," the company's website declares, and its recent activity in the cannabis market looks to support that mission.

    Becoming Cannabis Players

    While Pac Roots is distinctive in its approach and commitment to quality, it isn't the only company vying for market share in the flourishing cannabis sector.

    Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBFannounced that it has received regulatory approval for its acquisition of 100% of the membership interests of Gloucester Street Capital, the parent entity of Valley Agriceuticals LLC, via a merger between Gloucester and an indirect subsidiary of Cresco Labs. Valley Agriceuticals holds one of the 10 vertically integrated cannabis business licenses granted in the State of New York by the New York State Department of Health. Each license gives the operator the right to operate one cultivation facility and four dispensaries in New York. The acquisition is expected to close by the end of August.

    Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) recently released an update on its business operations, including the announcement of a new CEO, Miguel Martin. "Over the last six months, Aurora has focused on building the infrastructure and capabilities necessary for a successful and diversified business," said Aurora executive chairman and interim CEO Michael Singer. "The first phase of our business transformation, which is now substantially complete, included the rationalization of our cost structure, reduced capital spending, and a more prudent and targeted approach to capital deployment. As a result, we now have a far more efficient asset base and infrastructure to supply our key global markets. I am delighted to now be transitioning the CEO responsibilities to Miguel, and I am confident that Aurora is in a strong position to succeed under Miguel's leadership."

    Tilray Inc.'s (NASDAQ:TLRY) wholly owned subsidiary Tilray Portugal Unipessoal Lda. has received a Good Manufacturing Practice (GMP) certification in accordance with European Union standards, for its manufacturing facility in Cantanhede, Portugal. The certification expands the company's international export capacity to serve authorized medical cannabis markets and  provides authorization to complete medical cannabis extraction on-site as well as produce bulk extracts for the manufacture of medical cannabis oil as a finished product. The certification signals another milestone for Tilray's EU campus, which serves as the company's  international medical cannabis hub.

    Another player in the medical space is Arena Pharmaceuticals Inc. (NASDAQ:ARNA). The company has recognized a significant unmet opportunity for a targeted IBS pain treatment and is involved in a Phase 2, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of olorinab in patients with irritable bowel syndrome who are experiencing abdominal pain.

    In an industry anticipated to top $90 billion by 2027, strategic steps taken by companies operating in the cannabis space appear to reinforce the sector's promising future. Companies that focus on high-quality products through genetics while controlling costs could reap outsized market rewards  as the sector continues to grow and mature.

    For more information about Pac Roots, please visit Pac Roots Cannabis Corp. (CSE:PACR).

    About CannabisNewsWire

    CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

    To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

    For more information please visit https://www.CannabisNewsWire.com

    Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

    Do you have questions or are you interested in working with CNW? Ask our Editor

    CannabisNewsWire (CNW)
    Denver, Colorado
    www.CannabisNewsWire.com
    303.498.7722 Office

    CannabisNewsWire is part of the InvestorBrandNetwork.

    DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

    The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

    CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

    View Full Article Hide Full Article
  5. SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences:

    • Wells Fargo Virtual Healthcare Conference – Presenting on Wednesday, September 9, at 1:20 PM ET
    • Citi 2020 BioPharma Virtual Conference – Hosting investor meetings on Thursday, September 10
    • H.C. Wainwright Virtual Global Investment Conference – Presenting on Monday, September 14, at 9:30 AM ET
    • Cantor Virtual Global Healthcare Conference – Presenting on Wednesday, September 16, at 2:00 PM ET

    A live audio webcast of the available presentations will be posted under the investor relations section of Arena's website at www.arenapharm.com. A replay of…

    SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences:

    • Wells Fargo Virtual Healthcare Conference – Presenting on Wednesday, September 9, at 1:20 PM ET
    • Citi 2020 BioPharma Virtual Conference – Hosting investor meetings on Thursday, September 10
    • H.C. Wainwright Virtual Global Investment Conference – Presenting on Monday, September 14, at 9:30 AM ET
    • Cantor Virtual Global Healthcare Conference – Presenting on Wednesday, September 16, at 2:00 PM ET

    A live audio webcast of the available presentations will be posted under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentations will be available for 30 days following each event.

    About Arena Pharmaceuticals

    ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.

    In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.

    ARENA - Care More. Act Differently.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's participation in upcoming investor conferences and Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Corporate Contact:

    Megan E. Knight

    Arena Pharmaceuticals, Inc.

    Director, Investor Relations 



    858.210.3635

    Arena Media Contact: 

     

    858.453.7200 

    Arena Pharmaceuticals Logo

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-301124167.html

    SOURCE Arena Pharmaceuticals, Inc.

    View Full Article Hide Full Article
View All Arena Pharmaceuticals Inc. News